Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

  • There is currently no data for MXCT

MaxCyte

23 Jun 2025 18:00

RNS Number : 0278O
FTSE Russell
23 June 2025
 

 

 

Maxcyte Inc (UK): Constituent DeletionChanges in FTSE UK Index Series

23 June 2025

Subject to the expected cancellation of trading on AIM for Maxcyte Inc (UK, constituent), please see details of affected indexes and effective dates below:

 

 

Index

Effective FromStart of Trading

FTSE AIM 100 Index

26 June 2025

FTSE AIM All-Share Index

26 June 2025

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+61 (0) 2 7228 5659

Hong Kong

+852 2164 3333

Japan

+81 3 6441 1430

London

+44 (0) 20 7866 1810

New York

+1877 503 6437

Alternatively, please visit our website at lseg.com/ftse-russell

 

Terms of Use | Copyright © 2025 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FTSEALKDAEESEFA
Date   Source Headline
4th Dec 20197:00 amRNSAgreement with KSQ Therapeutics
21st Nov 20197:00 amRNSVor Biopharma Clinical and Commercial License
14th Nov 20197:00 amRNSPresentation at Jefferies Healthcare Conference
7th Nov 20197:00 amRNSMaxCyte to Present at BIO-Europe 2019
1st Nov 20191:04 pmRNSResult of AGM
24th Oct 20197:00 amRNSMaxCyte Advances Phase I Clinical Trial
23rd Oct 20197:01 amRNSPresentations at Cell & Gene Therapy Congress
8th Oct 20197:00 amRNSNotification of AGM and Audit Declaration
7th Oct 20197:00 amRNSEditas Clinical and Commercial License Agreement
30th Sep 20197:00 amRNSUpdates on CARMA Platform at Upcoming Meetings
18th Sep 20197:00 amRNSResults for the Six Months ended 30 June 2019
9th Sep 20197:00 amRNSPresentation at ICLE 2019
14th Aug 20197:00 amRNSNotice of Results
17th Jul 20197:00 amRNSTrading Update
11th Jul 20197:00 amRNSMaxCyte to Host Capital Markets Day Today
5th Jul 20194:42 pmRNSSecond Price Monitoring Extn
5th Jul 20194:36 pmRNSPrice Monitoring Extension
19th Jun 20197:00 amRNSAnnual Report
12th Jun 20197:00 amRNSAppointment of Joint Corporate Broker
29th May 20197:00 amRNSSave the Date: Capital Markets Day
8th May 20194:41 pmRNSSecond Price Monitoring Extn
8th May 20194:36 pmRNSPrice Monitoring Extension
8th May 20197:00 amRNSPhase I Clinical Trial of MCY-M11 Progressed
1st May 20197:00 amRNSASGCT Presentation on First CARMA Drug Candidate
24th Apr 20197:00 amRNSFinal Results for Year Ended 31 December 2018
8th Apr 20197:00 amRNSLaunch of ExPERTT Instrument Family
26th Mar 20197:00 amRNSNotice of Full Year Results
19th Mar 20195:05 pmRNSDirector Dealings
5th Mar 20197:00 amRNSGrant of Options
1st Mar 20197:00 amRNSClinical & Commercial Agreement with Kite
26th Feb 20195:32 pmRNSResult of Special Meeting and Issue of Equity
5th Feb 20194:32 pmRNSResults of Placing
5th Feb 20197:00 amRNSProposed Placing to raise a minimum of £10 million
15th Jan 20197:00 amRNSTrading Update
19th Dec 20187:00 amRNSChange of Auditor
17th Dec 20186:06 pmRNSDirector Dealings
21st Nov 20187:00 amRNSConsolidation of Trading Lines
20th Nov 20187:00 amRNSBlock Admission Six Monthly Return/TVR
16th Nov 20187:00 amRNSWebinar: non-viral cell engineering
14th Nov 20187:00 amRNSClinical and Commercial License Agreement
12th Nov 20187:00 amRNSMaxCyte Announces Research Agreement with Kite
9th Nov 20187:00 amRNSExpansion of CRISPR Commercial License Agreement
31st Oct 20184:25 pmRNSResult of AGM
10th Oct 20187:00 amRNSDosing Begins in First Clinical Trial of MCY-M11
8th Oct 20187:00 amRNSNotice of AGM
24th Sep 20187:00 amRNSResults for the Half Year ended 30 June 2018
10th Sep 20187:00 amRNSGrant of Options
3rd Sep 20187:00 amRNSNotice of Half Year Results
26th Jul 20185:33 pmRNSDirector/PDMR Shareholding
16th Jul 20187:00 amRNSFDA IND Clearance for First Clinical Programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.